Patients treated with a SGLT2 inhibitor had (1) a younger age (72 ± 9 versus 75 ± 8 years; P < 0.001), (2) a higher body mass index (24.2 ± 3.7 versus 23.1 ± 3.5 years; P = 0.002), a higher prevalence of (3) dyslipidemia (96.2% versus 88.9%; P = 0.008) and (4) coronary artery disease (65.4% versus 56.0%; P = 0.037), (5) higher HbA1c levels (7.7 ± 1.4% versus 7.2 ± 1.2% [61 ± 15 versus 55 ± 13 mmol/mol]; P < 0.001), and (6) a higher proportion of statin use (83.1% versus 70.3%; P = 0.001) than patients treated without a SGLT2 inhibitor. The gene discussed is SLC5A2; the disease is metabolic syndrome.